| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP &Chief Commercial Officer | VP, Marketing, Comm Strategy
2 companies
Northcott John serves as a SVP &Chief Commercial Officer at NKTR and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 0 buys and 6 sells. Those positions are worth an estimated $17.1M at current prices.
Historically, Northcott John's trades have earned a strong insider score of 79/100 across 5 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +74.6%.
The biggest single holding is NKTR (~$17.1M) as SVP &Chief Commercial Officer. The recent filings there lean toward selling, a net 43,140 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 16, 2022 | NKTR Nektar Therapeutics | SVP &Chief Commercial Officer | Sell | 4,592 | $3.95 | $18,138.40 | -2.0% | +26.5% | -81.6% | |
| Feb 16, 2022 | NKTR Nektar Therapeutics | SVP &Chief Commercial Officer | Sell | 4,852 | $10.95 | $53,129.40 | -2.1% | -64.8% | -73.4% | |
| Nov 16, 2021 | NKTR Nektar Therapeutics | SVP &Chief Commercial Officer | Sell | 6,061 | $13.16 | $79,762.76 | -3.0% | -18.3% | -73.5% | |
| Aug 16, 2021 | NKTR Nektar Therapeutics | SVP &Chief Commercial Officer | Sell | 6,192 | $13.83 | $85,635.36 | -3.0% | -3.1% | -66.0% | |
| May 17, 2021 | NKTR Nektar Therapeutics | SVP &Chief Commercial Officer | Sell | 6,085 | $18.30 | $111,355.50 | -2.9% | -24.3% | -78.3% | |
| Feb 16, 2021 | NKTR Nektar Therapeutics | SVP &Chief Commercial Officer | Sell | 15,358 | $22.37 | $343,558.46 | -6.7% | - | - |